Drug at center of multibillion-dollar ‘biosimilar’ fight sold for $40 million upfront

Makers of lower-cost biosimilars to AbbVie’s Humira looked to steal market share from the $80,000-a-year drug. It hasn’t turned out that way.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks